NasdaqGS:GILDBiotechs
Gilead’s Trodelvy Data Sparks Questions On Valuation And Oncology Growth
Gilead Sciences reported that Trodelvy combined with Keytruda produced significantly improved progression free survival in first line treatment of advanced PD L1 positive triple negative breast cancer.
The Phase 3 results were published in The New England Journal of Medicine with regulatory submissions filed at the same time.
The data support a potential expansion of Trodelvy’s use in breast cancer, adding to Gilead’s oncology efforts.
For investors tracking NasdaqGS:GILD, this update adds...